Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4551-4556

  Tsunoda, Toshiyuki ^a   Ishikura, Shuhei ^a   Doi, Keiko ^a   Matsuzaki, Hiroshi ^a   Iwaihara, Yuri ^a   Shirasawa, Senji ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

3D culture; Colorectal cancer; Luminal apoptosis; Resveratrol; Spheroid

Indexed keywords

CASPASE 3; RESVERATROL; PHOSPHODIESTERASE IV INHIBITOR; STILBENE DERIVATIVE;

APOPTOSIS; CANCER CELL CULTURE; COLORECTAL CANCER; CONFERENCE PAPER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; HCT116 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; QUANTITATIVE ASSAY; 3D CULTURE; ARTICLE; DRUG EFFECT; LUMINAL APOPTOSIS; SPHEROID;

3D CULTURE; COLORECTAL CANCER; LUMINAL APOPTOSIS; RESVERATROL; SPHEROID;

APOPTOSIS; HCT116 CELLS; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; STILBENES;

EID: 84907555363     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Fennema E, Rivron N, Rouwkema J, van Blitterswijk C and de Boer J: Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol 31: 108-115, 2013.
2. O'Brien LE, Zegers MM and Mostov KE: Opinion: Building epithelial architecture: insights from three-dimensional culture models. Nat Rev Mol Cell Biol 3: 531-537, 2002.
3. Griffith LG and Swartz MA: Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol 7: 211-224, 2006.
4. Shirasawa S, Furuse M, Yokoyama N and Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88, 1993.
5. Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, Tanaka Y, Kuroki M, Sasazuki T and Shirasawa S: Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. Neoplasia 12: 397-404, 2010.
6. Tsunoda T, Ota T, Fujimoto T, Doi K, Tanaka Y, Yoshida Y, Ogawa M, Matsuzaki H, Hamabashiri M, Tyson DR, Kuroki M, Miyamoto S and Shirasawa S: Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Mol Cancer 11: 46, 2012.
7. Spina D: PDE4 inhibitors: current status. Br J Pharmacol 155: 308-315, 2008.
8. Erdogan S and Houslay MD: Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J 321(Pt 1): 165-175, 1997.
9. Sengupta R, Sun T, Warrington NM and Rubin JB: Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci 32: 337-344, 2011.
10. Marquette A, Andre J, Bagot M, Bensussan A and Dumaz N: ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol 18: 584-591, 2011.
11. Kim SW, Rai D, McKeller MR and Aguiar RC: Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood 113: 6153-6160, 2009.
12. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA and Aguiar RC: The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 105: 308-316, 2005.
13. Meyers JA, Su DW and Lerner A: Chronic lymphocytic leukemia and B- and T-cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J Immunol 182: 5400-5411, 2009.
14. Chen TC, Wadsten P, Su S, Rawlinson N, Hofman FM, Hill CK and Schonthal AH: The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol Ther 1: 268-276, 2002.
15. Zhu J, Mix E and Winblad B: The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Rev 7: 387-398, 2001.
16. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V and Chung JH: Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433, 2012.
17. Baba I, Shirasawa S, Iwamoto R, Okumura K, Tsunoda T, Nishioka M, Fukuyama K, Yamamoto K, Mekada E and Sasazuki T: Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-RAS signaling pathway in human colon cancer cells. Cancer Res 60: 6886-6889, 2000.
18. Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Kuroki M, Sasazuki T and Shirasawa S: Oncogenic KRAS regulates miR-200c and miR- 221/222 in a 3D-specific manner in colorectal cancer cells. Anticancer Res 31: 2453-2459, 2011.
19. Ota T, Doi K, Fujimoto T, Tanaka Y, Ogawa M, Matsuzaki H, Kuroki M, Miyamoto S, Shirasawa S and Tsunoda T: KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res 32: 2271-2275, 2012.
20. Yoshida Y, Tsunoda T, Doi K, Fujimoto T, Tanaka Y, Ota T, Ogawa M, Matsuzaki H, Kuroki M, Iwasaki A and Shirasawa S: ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. Anticancer Res 32: 2301-2308, 2012.
21. Yoshida Y, Tsunoda T, Doi K, Tanaka Y, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A and Shirasawa S: KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res 31: 2535-2539, 2011.
22. Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK and Shirasawa S: The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate 69: 1398-1403, 2009.
23. Harikumar KB and Aggarwal BB: Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7: 1020-1035, 2008.
24. Carrizzo A, Forte M, Damato A, Trimarco V, Salzano F, Bartolo M, Maciag A, Puca AA and Vecchione C: Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 61: 215-226, 2013.
25. Huq F, Yu JQ, Beale P, Chan C, Arzuman L, Nessa MU and Mazumder ME: Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer. Anticancer Res 34: 541-545, 2014.
26. Wang W, Zhao C, Jou D, Lu J, Zhang C, Lin L and Lin J: Ursolic acid inhibits the growth of colon cancer-initiating cells by targeting STAT3. Anticancer Res 33: 4279-4284, 2013.
27. Fouad MA, Agha AM, Merzabani MM and Shouman SA: Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: calorie restriction is the force to the cytotoxicity. Hum Exp Toxicol 32: 1067-1080, 2013.
28. Carter LG, D'Orazio JA and Pearson KJ: Resveratrol and cancer: a focus on in vivo evidence. Endocr Relat Cancer 2012.
29. Juan ME, Alfaras I and Planas JM: Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 65: 584-591, 2012.